Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

ompound miravirsen, the International Nonproprietary Name (INN) or generic name for the compound formerly known as SPC3649.

Miravirsen, the first microRNA-targeted drug to enter human clinical trials, is a specific inhibitor of miR-122, a liver-specific microRNA that the Hepatitis C virus requires for replication. Unlike Hepatitis C therapies that directly target the virus, miravirsen works by removing a "helper" molecule (miR-122) that the virus needs in order to make new copies. Miravirsen is being studied in a Phase 1 trial multiple-ascending dose study in healthy volunteers and a Phase 2 study in patients infected with Hepatitis C is expected to begin in the second half of 2010.

Santaris Pharma A/S also has a broad range of drug discovery and development programs with its partners: Shire plc (lead candidates against up to five targets for rare genetic disorders), Pfizer (lead candidates against up to ten targets), GlaxoSmithKline (options to drug candidates from up to four viral disease programs) and Enzon Pharmaceuticals (lead candidates against eight cancer targets successfully delivered).

About Locked Nucleic Acid (LNA) Drug Platform

The LNA Drug Platform utilizing Santaris Pharma A/S proprietary LNA chemistry provides the key to delivering on the promise of RNA-targeted therapies today by addressing these concerns and overcoming the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity, which is only achievable with LNA-based drugs, allows this new class of drugs to potently and specifically inhibit RNA-targets in many different tissues without the need for complex delivery vehicles. LNA-based drugs are a promising new type of therapy that enables scientists to develo
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
(Date:10/30/2014)... Whitehouse Laboratories has formally announced a ... and Package Test Capacity. Responding to growing demands from ... increase in environmental chamber storage space that will enable ... samples to be securely held on site at Whitehouse ... has already taken place with the recent completion of ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/30/2014)... one of the key challenges in the development of ... physicists. , In a paper published today (28 October) ... colleagues show how to make a new type of ... devices, such as high-precision sensors and specialised superfast computers, ... But the methods for trapping these tiny particles are ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... 21, 2011 GeneLink, Inc. (OTCBB: GNLK.OB, ... company, reported financial results for the quarter ended September ... Chairman and CEO stated, "From a business development potential, ... in the history of the Company.  The Company continues ...
... The report " Leukemia Therapeutics ... Assessment & Global Market Forecast (2010 - 2020) ... restraints, and opportunities in North America, & Europe. ... TOC on Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & ...
... November 18, 2011 Percentage of revenues ... to medical relief organization building a hospital in Ethiopia ... scientific, technical and medical information products and services, announced ... Aid (ICA) through its "Pillars of Hope" ...
Cached Biology Technology:GeneLink Marketing Efforts Poised to Show Results 2GeneLink Marketing Efforts Poised to Show Results 3MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 3Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 2Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 3
(Date:10/30/2014)... This news release is available in German . ... we as individuals prompt our fellow humans to behave ... to social dilemmas in game theory. Previous studies assumed ... large groups. Nonetheless, scientists from the Max Planck Institute ... us can exert an influence on the cooperative behaviour ...
(Date:10/30/2014)... Biological membranes are mainly composed of lipid bilayers. ... ions onto lipid membranes helps clarify functional processes ... a quantitative description of the equilibria between lipid ... Zbigniew Figaszewski from the University of Bialystok, Poland, ... findings, just published in EPJ E . ...
(Date:10/29/2014)... to date, researchers have used DNA sequencing to uncover ... Joseph Buxbaum, Ph.D., Icahn School of Medicine at Mount ... of Harvard and MIT, and their colleagues examined more ... unrelated people. They identified changes in 107 genes that ... spectrum disorder (ASD) – a jump from the nine ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Ion adsorption matter in biology 2
... patients whose lungs are implanted with a pencil ... of lung function and report better quality of ... Frank C. Sciurba, M.D., reported today at CHEST ... of Chest Physicians. Scientific sessions continue through Thursday, ...
... home residents contract pneumonia, it is a blow to their ... Jean Mayer USDA Human Nutrition Research Center on Aging at ... concentration in the blood may help reduce the risk of ... data, it appears that daily zinc intake can help nursing ...
... activity in overweight children improves their thinking and reduces ... 200 overweight, inactive children ages 7-11 also showed that ... bone density. Is exercise a magic wand ... are still overweight but less so, with less fat, ...
Cached Biology News:Endobronchial valve significantly improves emphysema 2Zinc may reduce pneumonia risk in nursing home elderly 2Exercise improves thinking, reduces diabetes risk in overweight children 2Exercise improves thinking, reduces diabetes risk in overweight children 3
... to the third cytoplasmic loop of human ... KLH. The immunizing peptide has 79% homology ... Physical form: Solution in phosphate buffered saline, ... Titertest method: IHC (p). Titertest values: ...
... Hot Start Taq Monoclonal ... before the onset of ... amplification and primer-dimer formation. ... raised, the antibody is ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
... 5 Fluorescein 6-Fam, Hex, Tet ... Fluorescein Tamra Black Hole Quenchers ... Hex, Tet Tamra, Joe 3 ... Institute, New York Double labelled probes are ...
Biology Products: